The Biotechnology folio was developed for investors seeking aggressive capital growth with significant volatility.
The Biotechnology folio consists of large companies that range from drug therapy providers to genetic testing services.
Biotechnology companies have improved agricultural output for developing nations, enhanced the nutrition of foods, and produced medicines to cure or treat many different diseases. Breakthroughs are occurring throughout the industry and demand for biotech companies to produce more and better products could continue as science helps people live longer.
Last Updated: January 24, 2020
Inception Date: April 05, 2000
Date Funded: August 28, 2009*
|Year to Date||-3.87%||2.1%|
|1 Year Volatility||20.64%||11.65%|
* Returns reflect model performance from the Inception Date to the Date Funded, and funded performance since the Date Funded, if funded. Your returns may deviate significantly from the values displayed here, due to many factors, including how long after a strategy has been updated that you place orders to update your holdings.
Note: Tickers and weights for RTG Folios are only available when logged in.
There are generally 30 securities in the folio.
If the characteristics of the Folio have changed substantially, the securities included may change. Also, corporate actions, such as a merger, or other events may cause changes to the securities held at any time. Your returns may deviate significantly from the values displayed here, due to many factors, including how long after a folio has been updated that you place orders to update your holdings. RTGs are updated using market data from multiple sources including Zacks Investment Research ( www.zacks.com ), International Data Corporation (IDC) ( www.idc.com ), and other suppliers.